Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542299 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TP53SLC7A5KDM4ENFKB1 | |
| SCHEMBL3416543 | 0.77 | SLC7A5 (0.40) | TP53SLC7A5NFKB1CYP3A4TSHR | |
| SCHEMBL3416544 | 0.77 | SLC7A5 (0.40) | TP53SLC7A5NFKB1CYP3A4TSHR | |
| SCHEMBL10408938 | 0.77 | SLC7A5 (0.40) | TP53SLC7A5NFKB1CYP3A4TSHR | |
| SCHEMBL8604228 | 0.77 | TP53 (0.35) | TP53SLC7A5RAB9AMMEACE | |
| SCHEMBL2555426 | 0.77 | TGFBR1 (0.42) | ALDH1A1TP53SLC7A5KDM4E | |
| SCHEMBL12481867 | 0.77 | TGFBR1 (0.42) | ALDH1A1TP53SLC7A5KDM4E | |
| SCHEMBL1485441 | 0.75 | — | — | |
| SCHEMBL6756485 | 0.73 | SLC7A5 (0.37) | TP53SLC7A5 | |
| SCHEMBL6756484 | 0.73 | SLC7A5 (0.37) | TP53SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | disclosed |
| EP-3645031-A1 | PEPTIDE ANALOGS | Adepthera LLC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10328116-B2 | Combinations of proteasome inhibitors and cyclic peptides | BIG DNA LTD (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20190175687-A1 | Combination Therapy | BIG DNA LTD (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20190153059-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2019-05-23 | — | — | US | disclosed |
| US-20190135886-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2019-05-09 | — | — | US | disclosed |
| EP-2453900-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083304-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-1997002254-A1 | QUINAZOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339649-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885 |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | ALDH1A1 1313/4885TP53 3114/4885SLC7A5 83/4885 |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | ALDH1A1 2705/4885TP53 3970/4885SLC7A5 41/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | ALDH1A1 4712/4885TP53 4817/4885SLC7A5 1526/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885TP53 1622/4885SLC7A5 72/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885 |
| US-10328116-B2 | Combinations of proteasome inhibitors and cyclic peptides | PSMB3, PSMA3, PSMA6 | ALDH1A1 1474/4885TP53 2308/4885SLC7A5 3807/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885 |
| US-20190153059-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885TP53 4851/4885SLC7A5 2067/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | ALDH1A1 225/4885TP53 4747/4885SLC7A5 703/4885 |
| US-20190175687-A1 | Combination Therapy | PSMA6, PSMB3, PSMB6 | ALDH1A1 1272/4885TP53 2287/4885SLC7A5 3805/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | ALDH1A1 4712/4885TP53 4817/4885SLC7A5 1526/4885 |
| US-20190135886-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | GLP1R, GIPR, GCGR | ALDH1A1 4412/4885TP53 4305/4885SLC7A5 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.